Do analysts prefer SPRO or BGM?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Spero Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation & earnings, SPRO or BGM?

Spero Therapeutics has higher revenue and earnings than BGM Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Spero Therapeutics $54.77M 2.39 $8.57M $0.24 9.42 BGM Group $25.10M 1.45 -$1.44M N/A N/A

Do analysts prefer BGM or PEPG?

PepGen has a consensus target price of $11.50, suggesting a potential upside of 546.07%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 PepGen 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71

Which has higher valuation and earnings, BGM or PEPG?

BGM Group has higher revenue and earnings than PepGen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.45 -$1.44M N/A N/A PepGen N/A N/A -$89.65M -$1.75 N/A

Is BGM or PEPG more profitable?

BGM Group's return on equity of 0.00% beat PepGen's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A PepGen N/A -59.89% -49.62%

Do analysts prefer BGM or CNTB?

Connect Biopharma has a consensus price target of $7.17, suggesting a potential upside of 201.12%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Connect Biopharma 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88

Which has preferable earnings & valuation, BGM or CNTB?

BGM Group has higher revenue and earnings than Connect Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BGM Group $25.10M 1.45 -$1.44M N/A N/A Connect Biopharma $60K 2,497.41 -$55.48M -$1.15 N/A

Is BGM or CNTB more profitable?

BGM Group's return on equity of 0.00% beat Connect Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets BGM Group N/A N/A N/A Connect Biopharma N/A -122.29% -97.07%

Do analysts rate COYA or BGM?

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 152.61%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Coya Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coya Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.71 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable valuation and earnings, COYA or BGM?

BGM Group has higher revenue and earnings than Coya Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Coya Therapeutics $7.95M 17.91 -$21.23M -$1.15 N/A BGM Group $25.10M 1.45 -$1.44M N/A N/A

Do analysts recommend ALDX or BGM?

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 168.29%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than BGM Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aldeyra Therapeutics 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 BGM Group 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has preferable earnings and valuation, ALDX or BGM?

BGM Group has higher revenue and earnings than Aldeyra Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aldeyra Therapeutics N/A N/A -$33.85M -$0.46 N/A BGM Group $25.10M 1.45 -$1.44M N/A N/A

Is ALDX or BGM more profitable?

BGM Group's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aldeyra Therapeutics N/A -57.34% -36.33% BGM Group N/A N/A N/A

BGM Group (BGM) Competitors

$0.38 +0.05 (+16.09%)

Closing price 04:00 PM Eastern

Extended Trading

$0.37 -0.01 (-1.36%)

As of 07:16 PM Eastern

Compare

BGM vs. SPRO, PEPG, CNTB, COYA, and ALDX

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Spero Therapeutics (SPRO), PepGen (PEPG), Connect Biopharma (CNTB), Coya Therapeutics (COYA), and Aldeyra Therapeutics (ALDX). These companies are all part of the "pharmaceutical products" industry.

How does BGM Group compare to Spero Therapeutics?

Spero Therapeutics (NASDAQ:SPRO) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, media sentiment, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Spero Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, suggesting that its stock price is 81% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spero Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Spero Therapeutics has higher revenue and earnings than BGM Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spero Therapeutics	$54.77M	2.39	$8.57M	$0.24	9.42
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A

Spero Therapeutics has a net margin of 24.90% compared to BGM Group's net margin of 0.00%. Spero Therapeutics' return on equity of 35.58% beat BGM Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spero Therapeutics	24.90%	35.58%	24.95%
BGM Group	N/A	N/A	N/A

25.6% of Spero Therapeutics shares are held by institutional investors. 2.9% of Spero Therapeutics shares are held by insiders. Comparatively, 58.7% of BGM Group shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Spero Therapeutics and Spero Therapeutics both had 1 articles in the media. BGM Group's average media sentiment score of 1.89 beat Spero Therapeutics' score of 1.87 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Spero Therapeutics	Very Positive
BGM Group	Very Positive

Summary

Spero Therapeutics beats BGM Group on 8 of the 11 factors compared between the two stocks.

How does BGM Group compare to PepGen?

BGM Group (NASDAQ:BGM) and PepGen (NASDAQ:PEPG) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, dividends and analyst recommendations.

58.0% of PepGen shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 1.3% of PepGen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

BGM Group's return on equity of 0.00% beat PepGen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
PepGen	N/A	-59.89%	-49.62%

PepGen has a consensus target price of $11.50, suggesting a potential upside of 546.07%. Given PepGen's stronger consensus rating and higher probable upside, analysts clearly believe PepGen is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
PepGen	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

BGM Group has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market. Comparatively, PepGen has a beta of 1.93, indicating that its share price is 93% more volatile than the broader market.

BGM Group has higher revenue and earnings than PepGen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A
PepGen	N/A	N/A	-$89.65M	-$1.75	N/A

In the previous week, PepGen had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for PepGen and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.89 beat PepGen's score of 0.94 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
PepGen	Positive

Summary

BGM Group and PepGen tied by winning 6 of the 12 factors compared between the two stocks.

How does BGM Group compare to Connect Biopharma?

BGM Group (NASDAQ:BGM) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, institutional ownership, dividends, risk, earnings, media sentiment, analyst recommendations and profitability.

58.7% of Connect Biopharma shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 22.6% of Connect Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

BGM Group has higher revenue and earnings than Connect Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A
Connect Biopharma	$60K	2,497.41	-$55.48M	-$1.15	N/A

BGM Group has a beta of 1.81, indicating that its stock price is 81% more volatile than the broader market. Comparatively, Connect Biopharma has a beta of -0.22, indicating that its stock price is 122% less volatile than the broader market.

BGM Group's return on equity of 0.00% beat Connect Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Connect Biopharma	N/A	-122.29%	-97.07%

Connect Biopharma has a consensus price target of $7.17, suggesting a potential upside of 201.12%. Given Connect Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Connect Biopharma is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Connect Biopharma	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Connect Biopharma had 3 more articles in the media than BGM Group. MarketBeat recorded 4 mentions for Connect Biopharma and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.89 beat Connect Biopharma's score of 0.89 indicating that BGM Group is being referred to more favorably in the media.

Company	Overall Sentiment
BGM Group	Very Positive
Connect Biopharma	Positive

Summary

BGM Group and Connect Biopharma tied by winning 7 of the 14 factors compared between the two stocks.

How does BGM Group compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

BGM Group has higher revenue and earnings than Coya Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.95M	17.91	-$21.23M	-$1.15	N/A
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A

BGM Group has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. BGM Group's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
BGM Group	N/A	N/A	N/A

In the previous week, Coya Therapeutics had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Coya Therapeutics and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.89 beat Coya Therapeutics' score of 0.94 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Coya Therapeutics	Positive
BGM Group	Very Positive

Coya Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market.

39.8% of Coya Therapeutics shares are owned by institutional investors. 6.1% of Coya Therapeutics shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Coya Therapeutics currently has a consensus price target of $15.33, indicating a potential upside of 152.61%. Given Coya Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Coya Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BGM Group beats Coya Therapeutics on 8 of the 14 factors compared between the two stocks.

How does BGM Group compare to Aldeyra Therapeutics?

Aldeyra Therapeutics (NASDAQ:ALDX) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.

59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 11.8% of Aldeyra Therapeutics shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

BGM Group's return on equity of 0.00% beat Aldeyra Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aldeyra Therapeutics	N/A	-57.34%	-36.33%
BGM Group	N/A	N/A	N/A

Aldeyra Therapeutics presently has a consensus target price of $5.50, indicating a potential upside of 168.29%. Given Aldeyra Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Aldeyra Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aldeyra Therapeutics	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Aldeyra Therapeutics had 1 more articles in the media than BGM Group. MarketBeat recorded 2 mentions for Aldeyra Therapeutics and 1 mentions for BGM Group. BGM Group's average media sentiment score of 1.89 beat Aldeyra Therapeutics' score of 0.94 indicating that BGM Group is being referred to more favorably in the news media.

Company	Overall Sentiment
Aldeyra Therapeutics	Positive
BGM Group	Very Positive

Aldeyra Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, BGM Group has a beta of 1.81, indicating that its share price is 81% more volatile than the broader market.

BGM Group has higher revenue and earnings than Aldeyra Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aldeyra Therapeutics	N/A	N/A	-$33.85M	-$0.46	N/A
BGM Group	$25.10M	1.45	-$1.44M	N/A	N/A

Summary

BGM Group beats Aldeyra Therapeutics on 7 of the 12 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$36.47M	$3.65B	$6.84B	$12.44B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	N/A	21.29	25.83	24.36
Price / Sales	1.45	313.32	541.54	96.87
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	0.05	8.71	10.98	6.49
Net Income	-$1.44M	$23.87M	$3.57B	$336.61M
7 Day Performance	13.05%	4.23%	3.06%	0.90%
1 Month Performance	18.25%	1.71%	0.72%	-0.36%
1 Year Performance	-96.87%	69.92%	36.82%	31.26%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	0.7701 of 5 stars	$0.38 +16.1%	N/A	-97.3%	$36.47M	$25.10M	N/A	298	Positive News
SPRO Spero Therapeutics	1.7539 of 5 stars	$2.15 -2.7%	N/A	-23.1%	$127.96M	$66.80M	8.96	150	Gap Down
PEPG PepGen	3.138 of 5 stars	$1.82 -0.5%	$11.50 +531.9%	+47.8%	$126.58M	N/A	N/A	30	Gap Down
CNTB Connect Biopharma	4.4858 of 5 stars	$2.09 +5.0%	$7.20 +244.5%	+120.5%	$125.30M	$233K	N/A	110	News Coverage Analyst Forecast Gap Up
COYA Coya Therapeutics	2.3824 of 5 stars	$5.39 +1.9%	$15.33 +184.5%	-6.0%	$124.09M	$7.95M	N/A	6

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. SPRO, PEPG, CNTB, COYA, and ALDX

How does BGM Group compare to Spero Therapeutics?

Summary

How does BGM Group compare to PepGen?

Summary

How does BGM Group compare to Connect Biopharma?

Summary

How does BGM Group compare to Coya Therapeutics?

Summary

How does BGM Group compare to Aldeyra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. SPRO, PEPG, CNTB, COYA, and ALDX

How does BGM Group compare to Spero Therapeutics?

Which has more volatility & risk, SPRO or BGM?

Do analysts prefer SPRO or BGM?

Which has preferable valuation & earnings, SPRO or BGM?

Is SPRO or BGM more profitable?

Do institutionals and insiders hold more shares of SPRO or BGM?

Does the media favor SPRO or BGM?

Summary

How does BGM Group compare to PepGen?

Do insiders and institutionals hold more shares of BGM or PEPG?

Is BGM or PEPG more profitable?

Do analysts prefer BGM or PEPG?

Which has more risk and volatility, BGM or PEPG?

Which has higher valuation and earnings, BGM or PEPG?

Does the media refer more to BGM or PEPG?

Summary

How does BGM Group compare to Connect Biopharma?

Do insiders & institutionals believe in BGM or CNTB?

Which has preferable earnings & valuation, BGM or CNTB?

Which has more volatility and risk, BGM or CNTB?

Is BGM or CNTB more profitable?

Do analysts prefer BGM or CNTB?

Does the media prefer BGM or CNTB?

Summary

How does BGM Group compare to Coya Therapeutics?

Which has preferable valuation and earnings, COYA or BGM?

Is COYA or BGM more profitable?

Does the media refer more to COYA or BGM?

Which has more volatility & risk, COYA or BGM?

Do insiders and institutionals believe in COYA or BGM?

Do analysts rate COYA or BGM?

Summary

How does BGM Group compare to Aldeyra Therapeutics?

Do insiders & institutionals believe in ALDX or BGM?

Is ALDX or BGM more profitable?

Do analysts recommend ALDX or BGM?

Does the media favor ALDX or BGM?

Which has more volatility & risk, ALDX or BGM?

Which has preferable earnings and valuation, ALDX or BGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools